The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Wu, Zhiyuan ^a   Zhang, Xinju ^a   Xu, Xiao ^a   Chen, Yuming ^a   Hu, Tingting ^a   Kang, Zhihua ^a   Li, Shibao ^a   Wang, Hua ^a   Liu, Weiwei ^b   Ma, Xiaochao ^c   Guan, Ming ^a  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY   (China)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDER; NUCLEOTIDE SEQUENCE; PHILADELPHIA 1 CHROMOSOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CALRETICULIN; DNA MUTATIONAL ANALYSIS; FEMALE; GENOTYPE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; YOUNG ADULT;

EID: 84904518245     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-014-0048-6     Document Type: Article

References (41)

1. Editorial: some speculations on the myeloproliferative syndromes. W Dameshek, Blood 1951 6 372 375 14820991
2. A minute chromosome in human chronic granulocytic leukemia. PC Nowell, Science 1960 132 1497
3. S Swerdllow, E Campo, NL Harris, Who Classification Of Tumours Of Haematopoietic And Lymphoid Tissues IARC Press, France 2008
4. SM Lewis, BJ Bain, I Bates, JV Dacie, Dacie And Lewis Practical Haematology Elsevier Health Sciences, Philadelphia 2006
5. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. C James, V Ugo, J-P Le Couédic, J Staerk, F Delhommeau, C Lacout, L Garçon, H Raslova, R Berger, A Bennaceur-Griscelli, Nature 2005 434 1144 1148 10.1038/nature03546 15793561 (Pubitemid 40663494)
6. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. EJ Baxter, LM Scott, PJ Campbell, C East, N Fourouclas, S Swanton, GS Vassiliou, AJ Bench, EM Boyd, N Curtin, Lancet 2005 365 1054 1061 10.1016/S0140-6736(05)71142-9 15781101 (Pubitemid 40386783)
7. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. LM Scott, W Tong, RL Levine, MA Scott, PA Beer, MR Stratton, PA Futreal, WN Erber, MF McMullin, CN Harrison, N Engl J Med 2007 356 459 468 10.1056/NEJMoa065202 17267906 (Pubitemid 46193073)
8. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Y Pikman, BH Lee, T Mercher, E McDowell, BL Ebert, M Gozo, A Cuker, G Wernig, S Moore, I Galinsky, PLoS Med 2006 3 270 10.1371/journal.pmed. 0030270 16834459 (Pubitemid 44125998)
9. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, DP Steensma, MA Elliott, AP Wolanskyj, WJ Hogan, Blood 2006 108 3472 3476 10.1182/blood-2006-04-018879 16868251
10. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. A Tefferi, J Vardiman, Leukemia 2008 22 14 22 10.1038/sj.leu.2404955 17882280
11. Somatic mutations of calreticulin in myeloproliferative neoplasms. T Klampfl, H Gisslinger, AS Harutyunyan, H Nivarthi, E Rumi, JD Milosevic, NC Them, T Berg, B Gisslinger, D Pietra, N Engl J Med 2013 369 2379 2390 10.1056/NEJMoa1311347 24325356
12. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. J Nangalia, CE Massie, EJ Baxter, FL Nice, G Gundem, DC Wedge, E Avezov, J Li, K Kollmann, DG Kent, N Engl J Med 2013 369 2391 2405 10.1056/NEJMoa1312542 24325359
13. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. A Tefferi, J Thiele, A Vannucchi, T Barbui, Leukemia 2014 [Epub ahead of print]
14. Genetics: CALR mutations and a new diagnostic algorithm for MPN. A Tefferi, A Pardanani, Nat Rev Clin Oncol 2014 11 125 126 10.1038/nrclinonc.2014. 16 24514146
15. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJ Huntly, TJ Boggon, I Wlodarska, JJ Clark, S Moore, Cancer Cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627 (Pubitemid 40544655)
16. Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. AV Jones, NC Cross, HE White, AR Green, LM Scott, Haematologica 2008 93 1560 1564 10.3324/haematol.12883 18698085
17. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. A Theocharides, JR Passweg, M Medinger, R Looser, S Li, H Hao-Shen, AS Buser, A Gratwohl, A Tichelli, RC Skoda, Haematologica 2008 93 1890 1893 10.3324/haematol.13074 18790796
18. Development and inter-laboratory validation of unlabeled probe melting curve analysis for detection of JAK2 V617F mutation in polycythemia vera. Z Wu, H Yuan, X Zhang, W Liu, J Xu, W Zhang, M Guan, PLoS One 2011 6 26534 10.1371/journal.pone.0026534 22028900
19. A sensitive detection method for MPL W515L or MPL W515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. A Pancrazzi, P Guglielmelli, V Ponziani, G Bergamaschi, A Bosi, G Barosi, AM Vannucchi, J Mol Diagn 2008 10 435 441 10.2353/jmoldx.2008.080015 18669880
20. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. D Pietra, S Li, A Brisci, F Passamonti, E Rumi, A Theocharides, M Ferrari, H Gisslinger, R Kralovics, L Cremonesi, Blood 2008 111 1686 1689 10.1182/blood-2007-07-101576 17984312 (Pubitemid 351213460)
21. Characteristics and clinical correlates of MPL 515W> L/K mutation in essential thrombocythemia. AM Vannucchi, E Antonioli, P Guglielmelli, A Pancrazzi, V Guerini, G Barosi, M Ruggeri, G Specchia, F Lo-Coco, F Delaini, Blood 2008 112 844 847 10.1182/blood-2008-01-135897 18519816
22. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. PA Beer, PJ Campbell, LM Scott, AJ Bench, WN Erber, D Bareford, BS Wilkins, JT Reilly, HC Hasselbalch, R Bowman, Blood 2008 112 141 149 10.1182/blood-2008-01-131664 18451306
23. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. E Lippert, M Boissinot, R Kralovics, F Girodon, I Dobo, V Praloran, N Boiret-Dupré RC Skoda, S Hermouet, Blood 2006 108 1865 1867 10.1182/blood-2006-01-013540 16728702 (Pubitemid 44394995)
24. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. F Passamonti, E Rumi, D Pietra, C Elena, E Boveri, L Arcaini, E Roncoroni, C Astori, M Merli, S Boggi, Leukemia 2010 24 1574 1579 10.1038/leu.2010.148 20631743
25. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. A Pardanani, T Lasho, C Finke, C Hanson, A Tefferi, Leukemia 2007 21 1960 1963 10.1038/sj.leu.2404810 17597810 (Pubitemid 47299970)
26. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. F Passamonti, C Elena, S Schnittger, RC Skoda, AR Green, F Girodon, J-J Kiladjian, MF McMullin, M Ruggeri, C Besses, Blood 2011 117 2813 2816 10.1182/blood-2010-11-316810 21224469
27. JAK2 V617F and Exon 12 Genetic Variations in Korean Patients with BCR/ABL1-negative Myeloproliferative Neoplasms. JT Kim, YG Cho, SI Choi, YJ Lee, HR Kim, SJ Jang, DS Moon, YJ Park, G Park, Korean J Lab Med 2010 30 567 574 10.3343/kjlm.2010.30.6.567 21157140
28. Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. JH Ohyashiki, H Hisatomi, S Shimizu, M Sugaya, K Ohyashiki, Jpn J Clin Oncol 2009 39 509 513 10.1093/jjco/hyp048 19491085
29. High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera. Y-M Yeh, Y-L Chen, H-Y Cheng, W-C Su, N-H Chow, T-Y Chen, C-L Ho, Am J Clin Pathol 2010 134 266 270 10.1309/AJCPK7KGOWPHYWM0 20660330
30. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. S Schnittger, U Bacher, C Haferlach, T Geer, P Müller, J Mittermüller, P Petrides, R Schlag, R Sandner, J Selbach, Haematologica 2009 94 414 418 10.3324/haematol.13223 19252176
31. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. E Rumi, AS Harutyunyan, D Pietra, JD Milosevic, IC Casetti, M Bellini, NC Them, C Cavalloni, VV Ferretti, C Milanesi, Blood 2014 123 2416 2419 10.1182/blood-2014-01-550434 24553179
32. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. P Lundberg, A Karow, R Nienhold, R Looser, H Hao-Shen, I Nissen, S Girsberger, T Lehmann, J Passweg, M Stern, Blood 2014 123 2220 2228 10.1182/blood-2013-11-537167 24478400
33. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. A Tefferi, A Pardanani, K Lim, O Abdel-Wahab, T Lasho, J Patel, N Gangat, C Finke, S Schwager, A Mullally, Leukemia 2009 23 905 911 10.1038/leu.2009.47 19262601
34. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. A Tefferi, Leukemia 2010 24 1128 1138 10.1038/leu.2010.69 20428194
35. DNMT3A mutations in myeloproliferative neoplasms. F Stegelmann, L Bullinger, R Schlenk, P Paschka, M Griesshammer, C Blersch, S Kuhn, S Schauer, H Döhner, K Döhner, Leukemia 2011 25 1217 1219 10.1038/leu.2011.77 21537334
36. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. M Brecqueville, J Rey, F Bertucci, E Coppin, P Finetti, N Carbuccia, N Cervera, V Gelsi-Boyer, C Arnoulet, O Gisserot, Genes Chromosomes Cancer 2012 51 743 755 10.1002/gcc.21960 22489043
37. Why do we see JAK2 exon 12 mutations in myeloproliferative neoplasms&quest. I Vorechovsky, A Jones, N Cross, Leukemia 2013 27 1930 1932 10.1038/leu.2013.85 23511126
38. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. G Rotunno, C Mannarelli, P Guglielmelli, A Pacilli, A Pancrazzi, L Pieri, T Fanelli, A Bosi, AM Vannucchi, Blood 2014 123 1552 1555 24371211
39. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. E Rumi, D Pietra, V Ferretti, T Klampfl, AS Harutyunyan, JD Milosevic, NC Them, T Berg, C Elena, IC Casetti, Blood 2014 123 1544 1551 10.1182/blood-2014-01-550434 24366362
40. Calreticulin mutations and long-term survival in essential thrombocythemia. A Tefferi, E Wassie, T Lasho, C Finke, A Belachew, R Ketterling, C Hanson, A Pardanani, N Gangat, A Wolanskyj, Leukemia 2014 [Epub ahead of print]
41. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. U Gianelli, A Iurlo, D Cattaneo, G Lambertenghi-Deliliers, Expert Rev Hematol 2014 7 255 264 10.1586/17474086.2014.876898 24524231